Keywords
Masunetuzumab,Lunsumio,Bispecific antibody,bispecific,follicular lymphoma,non hodgkin's lymphoma,cd20,cd3,nhl,t-cell activation,immunotherapy,cytokine release syndrome,crs,b cell lymphoma,car-t therapy,epitope,Monoclonal,BsAb,BsmAB,bispecific monoclonal antibody,knob in hole,lock and key,trifunctional,igG-like,mAb,quadroma,hybridoma,round style,symmetrical,Antibody,Ab,immunoglobulin,Ig,immune system,adaptive immune system,immune,system,immunological,antigen-binding,antitoxin,agent,drug,antigen,competitor,ADC,antigen-binding site,heavy chain,light chain,y-shaped,disulfide bond,variable region,constant region,agglutinin,precipitin,seroglobulin,gamma globulin,Rectangular,Binding sites,simplified,immunoglobin,ig,protein,antibodies,fragment antibody binding,antibody fragment,immune system,soluble protein,sdAb,single-domain antibody,tail region,fc,fragment,Fc,fragment crystalizable region,link,bond,linker,disulfide bond,disulfide bridge,hinge region,antibody hinge,immunology,oncology,hematology,molecular biology,pharmacology,editable,proj-content-refinement-24q2
proj-content-refinement-antibodies-24q2,Masunetuzumab,Lunsumio,Bispecific antibody